The role of mTOR and phospho-p70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray

Table 4 Relationship between mTOR expression and clinicopathological features of gastric carcinomas

Clinicopathological features	n	mTOR expression
		-	+	++	+++	PR(%)	P value
Age(years)							0.042
<65	163	64	66	30	3	60.7
≥65	249	93	88	48	20	62.7
Sex							0.089
male	288	109	101	56	22	62.2
Female	124	48	53	22	1	61.3
Tumor size(cm)							0.457
<4	221	81	83	44	13	63.3
≥4	191	76	71	34	10	60.2
Depth of invasion							0.361
T_is-1	222	79	86	45	12	64.4
T_2-4	190	78	68	33	11	58.9
Lymphatic invasion							0.845
-	267	99	103	51	14	62.9
+	145	58	51	27	9	60.0
Venous invasion							0.063
-	358	140	135	66	17	60.9
+	54	17	19	12	6	68.5
Lymph node metastasis							0.168
-	263	90	105	55	13	65.8
+	149	67	49	23	10	55.0
UICC staging							0.898
0-I	234	87	90	45	12	62.8
II-IV	178	70	64	33	11	60.7
Lauren classification							0.000
Intestinal type	230	71	84	56	19	69.1
Diffuse type	173	81	67	21	4	53.2
Cytoplasmic P70S6K expression							0.000
-	207	109	72	22	4	47.3
+~+++	151	27	57	48	19	82.1
Nuclear P70S6K expression							0.000
-	162	95	48	15	4	41.4
+~+++	206	39	90	58	19	81.1

PR = positive rate; T_is = carcinoma in situ; T₁ = lamina propria and submucosa; T₂ = muscularis propria and subserosa; T₃ = exposure to serosa; T₄ = invasion into serosa; UICC = Union Internationale Contre le Cancer

ISSN: 1756-9966